Maria T. Palomares-Lois

A Coruna, GA, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Real-World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry.

Real-World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry.

Journal: Alimentary pharmacology & therapeutics

Published: March 28, 2026

Effectiveness and safety of dual advanced therapy in inflammatory bowel disease: a multicenter series from Galicia, Spain.

Effectiveness and safety of dual advanced therapy in inflammatory bowel disease: a multicenter series from Galicia, Spain.

Journal: Revista espanola de enfermedades digestivas

Published: September 29, 2025

Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study.

Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study.

Journal: Alimentary pharmacology & therapeutics

Published: June 09, 2024

Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety.

Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety.

Journal: The American journal of gastroenterology

Published: July 13, 2022

Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn's Disease Patients on Ustekinumab.

Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn's Disease Patients on Ustekinumab.

Journal: Journal of clinical medicine

Published: June 10, 2022

Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study. J. Clin. Med. 2021, 10, 2885.

Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study. J. Clin. Med. 2021, 10, 2885.

Journal: Journal of clinical medicine

Published: May 26, 2022

Pharmacokinetic and clinical monitoring through posologic changes in adalimumab intensification regimen from 40 mg every week to 80 mg every other week.

Pharmacokinetic and clinical monitoring through posologic changes in adalimumab intensification regimen from 40 mg every week to 80 mg every other week.

Journal: Revista espanola de enfermedades digestivas

Published: February 16, 2022

Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study.

Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study.

Journal: Inflammatory bowel diseases

Published: September 10, 2021

Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study.

Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study.

Journal: Journal of clinical medicine

Published: May 19, 2021

Crohn's disease in patients treated with etanercept.

Crohn's disease in patients treated with etanercept.

Journal: Revista espanola de enfermedades digestivas

Published: December 04, 2019

Lymphoplasmacytic inflammatory pseudotumor of the liver

Lymphoplasmacytic inflammatory pseudotumor of the liver

Journal: Anales del sistema sanitario de Navarra

Published: September 08, 2016

Showing 1-11 of 11

Last Updated: 09/26/2026